Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia

Free Radical Research

Volumn 43, Issue 5, 2009, Pages 485-491

  Jirasomprasert, Totsapol ^a   Morales, Noppawan Phumala ^a   Limenta, Lie M G ^a,b   Sirijaroonwong, Srisuporn ^a   Yamanont, Paveena ^a   Wilairat, Prapin ^a   Fucharoen, Suthat ^c   Chantharaksri, Udom ^a  

^a Mahidol University ^*  (Thailand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Ascorbyl radical; Beta thalassemia; Deferiprone; EPR; Pro oxidant; Spin trapping

Indexed keywords

5,5 DIMETHYL 1 PYRROLINE 1 OXIDE; ASCORBIC ACID; BILIRUBIN; CARBON; DEFERIPRONE; FREE RADICAL; HEMOGLOBIN E; IRON; MW 139; TERT BUTYL HYDROPEROXIDE; TRANSFERRIN; UNCLASSIFIED DRUG; 5,5-DIMETHYL-1-PYRROLINE-1-OXIDE; AMINE OXIDE; DEHYDROASCORBIC ACID; DRUG DERIVATIVE; IRON CHELATING AGENT; OXIDIZING AGENT; PYRIDONE DERIVATIVE; SEMIDEHYDROASCORBIC ACID;

ADULT; AGRANULOCYTOSIS; ARTHRITIS; ARTHROPATHY; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ELECTRON SPIN RESONANCE; FEMALE; HUMAN; IRON BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; OXIDATION; SIGNAL PROCESSING; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; SPIN TRAPPING;

ADULT; BETA-THALASSEMIA; CYCLIC N-OXIDES; DEHYDROASCORBIC ACID; ELECTRON SPIN RESONANCE SPECTROSCOPY; FEMALE; FREE RADICALS; HUMANS; IRON; IRON CHELATING AGENTS; MALE; OXIDANTS; PYRIDONES; SPIN TRAPPING; YOUNG ADULT;

EID: 67650175472     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760902870611     Document Type: Article

References (36)

1. Walter, PB, Fung, EB, Killilea, DW, Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E. and Harmatz, P. (2006) Oxidative stress and inflammation in iron overloaded patients with β-thalassemia or sickle cell disease. Br J Haematol, 135, pp. 254-263.
2. Weatherall, DJ. (1998) Pathophysiology of thalassaemia. Baillieres Clin Haematol, 11, pp. 127-146.
3. Borgna-Pignatti, C., Cappellini, MD, De Stefano, P., Del Vecchio, GC, Forni, GL, Gamberini, MR, Ghilardi, R., Origa, R., Piga, A., Romeo, MA, Zhao, H. and Cnaan, A. (2005) Survival and complication in thalassemia. Ann NY Acad Sci, 1054, pp. 40-47.
4. Borgna-Pignatti, C., Cappellini, MD, De Stefano, PD, Del Vecchio, GC, Forni, GL, Gamberini, MR, Ghilardi, R., Romeo, MA, Zhao, H. and Cnaan, A. (2006) Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood, 107, pp. 3733-3737.
5. Balfour, JAB and Foster, RH. (1999) Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs, 58, pp. 553-578.
6. Glickstein, H., El, RB, Shvartsman, M. and Cabantchik, ZI. (2005) Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells. Blood, 106, pp. 3242-3250.
7. Piga, A., Gaglioti, C., Fogliacco, E. and Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica, 88, pp. 489-496.
8. Kontoghiorghes, GJ, Neocleous, K. and Kolnagou, A. (2003) Benefits and risks of deferiprone in iron overload in thalassemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Safety, 26, pp. 553-584.
9. Motekitis, RJ and Martell, AE. (1991) Stabilization of the iron (III) chelates of 1, 2-dimethyl-3-hydroxypyrid-4-ones and related ligands. Inorg Chim Acta, 183, pp. 71-80.
10. Devanur, LD, Neubert, H. and Hider, RC. (2008) The Fenton activity of iron (III) in the presence of deferiprone. J Pharm Sci, 97, pp. 1454-1467.
11. Winichagoon, P., Fucharoen, S., Chen, P. and Wasi, P. (2000) Genetic factors affecting clinical severity in β-thalassemia syndromes. J Pediatr Hematol Oncol, 22, pp. 573-580.
12. Limenta, LMG, Jirasomprasert, T., Tankanitlert, J., Svasti, S., Wilairat, P., Chantraraksri, U., Fucharoen, S. and Morales, NP. (2008) UGT1A6 genetype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol, 65, pp. 908-916.
13. Jittangprasert, P., Wilairat, P. and Pootrakul, P. (2004) Comparison of colorimetry and electrothermal atomic absorption spectroscopy for the quantification of non-transferrin bound iron in human sera. Southeast Asia J Trop Med Public Health, 35, pp. 1039-1044.
14. Janzen, EG, Jandrisits, LT, Shetty, RV, Haire, DL and Hilborn, JW. (1989) Synthesis and purification of 5,5-dimethyl-1-pyrroline-N-oxide for biological applications. Chem Biol Interact, 70, pp. 167-172.
15. International Committee for Standardization in Hematology (ICSH) (1978) Recommendations for measurement for total and unsaturated iron binding capacity in serum. Br J Haematol, 38, pp. 281-287.
16. International Committee for Standardization in Hematology (ICSH) (1978) Recommendations for measurement of serum iron in human blood. Br J Haematol, 38, pp. 291-294.
17. Laroff, GP, Fessenden, RW and Schuler, RH. (1972) The electron spin resonance spectra of radical intermediates in the oxidation of ascorbic acid and related substances. J Am Chem Soc, 94, pp. 9062-9080.
18. Nishi, J., Ogura, R., Sugiyama, M., Hidaka, T. and Kohno, M. (1991) Involvement of active oxygen in lipid peroxide radical reaction of epidermal homogenate following ultraviolet light exposure. J Invest Dematol, 97, pp. 115-119.
19. Cragg, L., Hebbel, RP, Miller, W., Solovey, A., Selby, S. and Enright, H. (1998) The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood, 92, pp. 632-638.
20. Dean, RT and Nicholson, P. (1994) The action of nine chelators on iron dependent radical damage. Free Radic Res, 20, pp. 83-101.
21. Morel, I., Sergent, O., Cogrel, P., Lescoat, G., Pasdeloup, N., Brissot, P., Cillard, P. and Cillard, J. (1995) EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron loaded hepatocyte culture: Comparison with that of deferrioxamine. Free Radic Biol Med, 18, pp. 303-310.
22. Matthews, AJ, Vercellotti, GM, Menchaca, HJ, Bloch, PH, van Michalek, N., Marker, PH, Murar, J. and Buchwald, H. (1997) Iron and atherosclerosis: Inhibition by iron chelator deferiprone (L1). J Surg Res, 73, pp. 35-50.
23. van der Kraaij, AM, van Eijk, HG and Koster, JF. (1989) Prevention of postischemic cardiac injury by the orally active iron chelator 1, 2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation, 80, pp. 158-164.
24. Buettner, GR and Jukiewicz, BA. (1993) Ascorbate free radical as a marker of oxidative stress. An EPR study. Free Radic Biol Med, 14, pp. 49-55.
25. Buettner, GR. (1990) Ascorbate oxidation: UV absorbance of ascorbate and ESR spectroscopy of ascorbyl radical as assays for iron. Free Radic Res Commun, 10, pp. 5-9.
26. Buettner, GR. (1988) In the absence of catalytic metals ascorbate does not autooxidize at pH 7: Ascorbate as a test for catalytic metals. J Biochem Biophys Methods, 16, pp. 27-40.
27. Pietri, S., Seguin, JR, D'Arbigny, P. and Culcasi, M. (1994) Ascorbyl free radical: A noninvasive marker of oxidative stress in human open-heart surgery. Free Radic Biol Med, 16, pp. 523-528.
28. Buettner, GR and Chamulitrat, W. (1990) The catalytic activity of iron in synovial fluid as monitored by the ascorbate free radical. Free Radic Biol Med, 8, pp. 55-56.
29. Morales, NP, Chalermchoung, C., Fucharoen, S. and Chantharaksri, U. (2007) Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients. Clin Chem Lab Med, 45, pp. 884-889.
30. Luechapudiporn, R., Morales, NP, Fucharoen, S. and Chantharaksri, U. (2006) The reduction of cholesteryl linoleate in lipoproteins; an index of clinical severity in β-thalassemia/Hb E. Clin Chem Lab Med, 44, pp. 574-581.
31. Breuer, W., Hershko, C. and Cabantchik, ZI. (2003) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci, 23, pp. 185-192.
32. Esposito, BP, Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. and Cabantchik, ZI. (2003) Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood, 102, pp. 2670-2677.
33. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. and Cabantchik, ZI. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/ Hb E patients treated with an oral chelator. Blood, 104, pp. 1504-1510.
34. Phumala, N., Porasuphatana, S., Unchern, S., Pootrakul, P., Fucharoen, S. and Chantharaksri, U. (2003) Hemin: A possible cause of oxidative stress in blood circulation of β-thalassemia/hemoglobin E disease. Free Radic Res, 37, pp. 129-135.
35. Mason, RP and Fischer, V. (1992) Possible role of free radical formation in drug-induced agranulocytosis. Drug Saf, 7, pp. 45-50.
36. Berkovitch, M., Laxer, RM, Inman, R., Koren, G., Pritzker, KP, Fritzler, MJ and Olivieri, NF. (1994) Arthropathy in thalassaemia patients receiving deferiprone. Lancet, 343, pp. 1471-1472.